key: cord-0766864-3yqwnfwt authors: SeyedAlinaghi, SeyedAhmad; Karimi, Amirali; Barzegary, Alireza; Pashaei, Zahra; Afsahi, Amir Masoud; Alilou, Sanam; Janfaza, Nazanin; Shojaei, Alireza; Afroughi, Fatemeh; Mohammadi, Parsa; Soleimani, Yasna; Nazarian, Newsha; Amiri, Ava; Tantuoyir, Marcarious M.; Oliaei, Shahram; Mehraeen, Esmaeil; Dadras, Omid title: Mucormycosis infection in patients with COVID‐19: A systematic review date: 2022-02-28 journal: Health Sci Rep DOI: 10.1002/hsr2.529 sha: 80047b7122c91c39fe2d742ce561fa34a2680cdb doc_id: 766864 cord_uid: 3yqwnfwt INTRODUCTION: Several reports previously described mucormycosis co‐infection in patients with COVID‐19. As mucormycosis and COVID‐19 co‐infection might adversely affect patients' outcomes, we aimed to systematically review the related evidence and the subsequent outcomes. METHODS: We conducted a systematic review of relevant articles searching the keywords in the online databases of PubMed, Scopus, Embase, Cochrane, and Web of Science. All the records from the start of the pandemic until June 12th, 2021 underwent title/abstract and then full‐text screening process, and the eligible studies were included. We did not include any language or time restrictions for the included studies. RESULTS: We found 31 eligible studies reporting 144 total cases of COVID‐19 and mucormycosis co‐infection. The nose, cranial sinuses, and orbital cavity were the most commonly involved organs, although the cerebrum, lungs, and heart were also involved in the studies. Pre‐existing diabetes mellitus (DM), as well as corticosteroid use, were the most commonly identified risk factors, but other underlying conditions and immunomodulatory drug use were also present in several cases. Aspergillus was the most commonly reported micro‐organism that caused further co‐infections in patients with concurrent COVID‐19 and mucormycosis. As most of the studies were case reports, no reliable estimate of the mortality rate could be made, but overall, 33.6% of the studied cases died. CONCLUSION: Early diagnosis of mucormycosis co‐infection in COVID‐19 patients and selecting the right treatment plan could be a challenge for physicians. Patients with underlying co‐morbidities, immunocompromised patients, and those receiving corticosteroids are at higher risk of developing mucormycosis co‐infection and it is crucial to have an eye examination for early signs and symptoms suggesting a fungal infection in these patients. the most commonly reported micro-organism that caused further co-infections in patients with concurrent COVID-19 and mucormycosis. As most of the studies were case reports, no reliable estimate of the mortality rate could be made, but overall, 33 .6% of the studied cases died. Conclusion: Early diagnosis of mucormycosis co-infection in COVID-19 patients and selecting the right treatment plan could be a challenge for physicians. Patients with underlying co-morbidities, immunocompromised patients, and those receiving corticosteroids are at higher risk of developing mucormycosis co-infection and it is crucial to have an eye examination for early signs and symptoms suggesting a fungal infection in these patients. [1] [2] [3] [4] COVID-19 causes several symptoms and can precipitate severe multiorgan involvements, acute respiratory distress syndrome (ARDS), and death. [5] [6] [7] Cases of bacterial or fungal co-infections or super-infections have been reported in previous studies and can increase the mortality rates and complications of COVID-19. 8, 9 Several reports of COVID-19 and mucormycosis co-infection exist. 10 Although antibiotics and systemic corticosteroids could reduce the risk of severe COVID-19 complications and bacterial co-or super-infection, they can provide a favorable condition for opportunistic infections, such as mucormycosis. [11] [12] [13] Mucormycosis, also commonly knowns as the disease caused by the black fungus, is a rare and life-threatening fungal infection with various ranges of involvement. 14, 15 A previous systematic review reported an enormous 33.6% mortality rate in patients co-infected with mucormycosis and COVID- 19. 16 This potentially deadly black fungus can affect various organs and systems. 14, 15 Rhino-orbital, pulmonary, oral, cerebral, sinonasal, and gastrointestinal mucormycosis are some of the sites of involvement in mucormycosis. 9, 17, 18 Underlying diseases such as poorly controlled diabetes mellitus (DM), hematological malignancies, or immunocompromised state are predisposing factors to mucormycosis infection. 9, 19, 20 Early diagnosis and treatment can reduce the mortality rate and improve the outcome. Understanding this condition may improve the diagnosis and quality of care of the COVID-19 patients co-infected with mucormycosis. Therefore, we aimed to systematically review mucormycosis co-infection in patients with COVID-19 and its subsequent outcomes. This systematic review was conducted to establish the risk factors for mucormycosis co-infection in patients with COVID-19, the target organs for mucormycosis in the co-infected patients, the diagnosis time between the COVID-19 and mucormycosis infection, the provided treatments and the mortality of the co-infected patients, and other further co-infections in the patients co-infected with COVID-19 and mucormycosis. This is a comprehensive review to shed light on the incidence of fungus mucormycosis in COVID patients based on the current evidence. To authenticate the end results this investigation benefits from the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist. We systematically searched the keywords in the online databases of We aimed to include the original studies that reported mucormycosis co-infection in patients with COVID-19. We downloaded the records into the EndNote software and then excluded the duplicate records using the software. Then, the remaining duplicates were excluded manually and the records got ready to enter the two-phase screening process. To select and include pertinent literature, two of our research staff read and selected the eligible studies based on their titles and abstracts. At the next step, we inspected the full texts of these studies carefully, and finally, the studies that adhered to the inclusion criteria were included in the qualitative synthesis. Original studies published in any language that met the aim of our study, that is, those including COVID-19 patients with confirmed or suspected mucormycosis co-infection, were included. We did not include any language or time restrictions for the included studies. We included all the peer-reviewed original studies, case reports and case series. The exclusion criteria for this study were as follows: 1. Non-original studies, such as reviews, systematic reviews, metaanalyses, or editorials without original reports. Invasive mucormycosis was noted in one patient (PM5, Figure 1 ) and confirmed with Mucoralesspecific PCR. The mucormycosis was vasculocentric and disseminated, involving the hilar lymph nodes, heart, brain, and kidney in the same patient. Macroscopic (two [23%] of nine patients) and microscopic (eight [89%] of nine) pulmonary thromboemboli were frequent observations. Invasive mucormycosis was noted in one patient (PM5, Figure 1 ) and confirmed with Mucorales- In this study, 162 documents were retrieved using a systematic search strategy. After a primary review of retrieved articles, 94 duplicates were and mucormycosis (the sample size of these studies were 36 and eight), 13, 21 and four case reports from France (two studies), India, and the United States. 14, 20, 22, 23 Amphotericin B was the most prescribed treatment given in 92% of the patients. As many of the studies were case reports and patients either died or recovered, the mortality rates ranged from 0% to 100% (Table 1) diagnosis, with a mean interval of 25.6 days. In addition, a co-infection with a third micro-organism was occasionally reported, mainly with aspergillosis. We found a mortality rate of 45/134 (33.6%). However, as many of the included studies were case reports, the mortality rate was either not reported or described as 0% for those who survived or 100% for those who died due to mucormycosis co-infection; therefore, the mean mortality rate is not reliable. In addition to systemic corticosteroids, our studies described immunomodulatory drugs (such as tocilizumab) and voriconazole intake among their cases. In this matter, immunomodulatory drugs such as tocilizumab increased the co-infection susceptibility in one study. 59 Also, published studies have demonstrated an increased risk of mucormycosis in patients who received voriconazole. 60 Some of our studies reported lymphoma, leukemia, and solid organ transplant cases in table. 10, 11, 14, [21] [22] [23] [24] 27, 40 As the new coronavirus gained mainstream attention among infectious diseases, less and less attention has been given to fungal infections. Meanwhile, the diversity of COVID-19 symptoms overshadowed the other probable pathological conditions of COVID-19 patients, due to which the diagnosis of many fungal co-infections has been delayed. Thus, the relatively small number of published studies reporting mucormycosis co-infection in COVD-19 patients was the main limitation concerning the aim of this paper. In addition, the small sample size in each study and extreme mortality rates in case reports and case series hindered a comparison between the mortality rate of single COVID-19 infection and mucormycosis co-infection. Furthermore, most studies were case reports or small case series that may introduce biases to the study, for example, they may report specific circumstances that occur rarely in the real world but are emphasized in case reports. The mucormycosis co-infection in COVID-19 patients is of great concern as it raises mortality and delay diagnosis is probable in the setting of COVID-19. In addition, the lung involvement caused by the COVID-19 infection could often worsen by the mucormycosis fungal infection and the patient, therefore, has a higher risk of mortality or developing a serious medical condition. Furthermore, the diagnosis of mucormycosis co-infection plays an important role in determining the patient's treatment plan, as corticosteroids, a treatment choice for COVID-19, is simultaneously a risk factor for mucormycosis infection. To Effects of COVID-19 prevention procedures on other common infections: a systematic review Characterization of SARS-CoV-2 different variants and related morbidity and mortality: a systematic review The clinical outcomes of COVID-19 in HIV-positive patients: a systematic review of current evidence The effects of hyperbaric oxygen therapy (HBOT) on coronavirus disease-2019 (COVID-19): a systematic review Genetic susceptibility of COVID-19: a systematic review of current evidence Late complications of COVID-19; a systematic review of current evidence Effects of androgen deprivation therapy on COVID-19 in patients with prostate cancer: a systematic review and meta-analysis Clinical characteristics of COVID-19 patients with clinically diagnosed bacterial co-infection: a multi-center study Rhinocerebral Mucormycosis and COVID-19 pneumonia Mucormycosis associated with covid19 in two kidney transplant patients Susceptibility of severe COVID-19 patients to rhino-orbital mucormycosis fungal infection in different clinical manifestations Rhino-orbital mucormycosis during steroid therapy in COVID-19 patients: a case report Imaging spectrum of acute invasive fungal rhinoorbital-cerebral sinusitis in COVID-19 patients: a case series and a review of literature Coronavirus disease (Covid-19) associated Mucormycosis (CAM): case report and systematic review of literature Histopathological findings and viral tropism in UKpatients with severe fatal COVID-19: a postmortem study Mucormycosis in COVID-19: a systematic review of cases reported worldwide and in India Secondary infection with rhino-orbital cerebral mucormycosis associated with COVID-19 Rare and fatal gastrointestinal Mucormycosis (Zygomycosis) in COVID-19 patient: a case report Acute invasive rhinoorbital mucormycosis in a patient with COVID-19-associated acute respiratory distress syndrome Pulmonary aspergillosis and mucormycosis in a patient with COVID-19 Invasive fungal sinusitis in post COVID-19 patients: a new clinical entity Mixed mold infection with Aspergillus fumigatus and Rhizopus microsporus in a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) patient Occurrence of invasive pulmonary fungal infections in patients with severe COVID-19 admitted to the ICU Euro surveillance: bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin A fatal case of Rhizopus azygosporus pneumonia following COVID-19 Fulminant mucormycosis complicating coronavirus disease 2019 (COVID-19) Mucormycosis after coronavirus disease 2019 infection in a heart transplant recipient -case report and review of literature Maxillofacial infections in Covid-19 era-actuality or the unforeseen: 2 case reports Autoptic identification of disseminated mucormycosis in a young male presenting with cerebrovascular event, multi-organ dysfunction and COVID-19 infection Sinoorbital mucormycosis in a COVID-19 patient: A case report Rhino-orbital Mucormycosis associated with COVID-19 Orbital infarction syndrome secondary to rhino-orbital mucormycosis in a case of COVID-19: Clinicoradiological features Rise of the phoenix: Mucormycosis in COVID-19 times COVID-19 triggering mucormycosis in a susceptible patient: a new phenomenon in the developing world? Title of the article: Paranasal Mucormycosis in COVID-19 patient COVID-19 and orbital mucormycosis Mucor in a viral land: a tale of two pathogens A case of fatal rhino-orbital mucormycosis associated with new onset diabetic ketoacidosis and COVID-19 Mucormycosis with orbital compartment syndrome in a patient with COVID-19 Autopsy proven pulmonary Mucormycosis due to Rhizopus microsporus in a critically ill COVID-19 patient with underlying hematological malignancy Rhino-orbital-cerebralmucormycosis in COVID-19: a systematic review A prospective study of mucormycosis in North India: experience from a tertiary care hospital A prospective multicenter study on mucormycosis in India: epidemiology, diagnosis, and treatment When uncontrolled diabetes mellitus and severe COVID-19 converge: the perfect storm for Mucormycosis High prevalence of COVID-19-associated diabetic ketoacidosis in UKsecondary care Rhinocerebral mucormycosis in COVID-19 patient with diabetes a deadly trio: case series from the north-western part of India Association between Administration of Systemic Corticosteroids and Mortality among Critically ill Patients with COVID-19: a meta-analysis Glucocorticoids and invasive fungal infections Clinical and immunological features of severe and moderate coronavirus disease 2019 Iron: innocent bystander or vicious culprit in COVID-19 pathogenesis? COVID-19 as part of the hyperferritinemic syndromes: the role of iron depletion therapy Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes COVID-19 endocrinopathy with hindsight from SARS Pathogenesis of mucormycosis Endothelial cell infection and endotheliitis in COVID-19 Pulmonary vascular Endothelialitis, thrombosis, and angiogenesis in Covid-19 Molecular mechanisms of mucormycosis-the bitter and the sweet High GRP78 levels in Covid-19 infection: a case-control study IL-6 inhibition in critically ill COVID-19 patients is associated with increased secondary infections Voriconazoleassociated zygomycosis: a significant consequence of evolving antifungal prophylaxis and immunosuppression practices? Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the mycoses study group education and research consortium A multicentre observational study on the epidemiology, risk factors, management and outcomes of mucormycosis in India Global epidemiology of Mucormycosis Coronavirus disease 2019: what we know Epidemiology and pathophysiology of COVID-19-associated mucormycosis: India versus the rest of the world Current understanding in the pathophysiology of SARS-CoV-2-associated rhino-Orbito-cerebral Mucormycosis: a comprehensive review COVID-19 Associated Mucormycosis: the Urgent Need to Reconsider the Indiscriminate Use of Immunosuppressive Drugs Mucormycosis infection in patients with COVID-19: A systematic review The present study was conducted in collaboration with Khalkhal Esmaeil Mehraeen affirms that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained. The authors confirm that the data supporting the findings of this study are available within the article.